§
Luxuse
Patent Intelligence
Sign In
← Back to Patent Explorer
US4769387A Expired / Lapsed US ⏱️ 0.0 years remaining

Dibenzofuran lipoxygenase inhibiting compounds, compositions and use

Assignee: Abbott Laboratories
•
Filing: 1987-11-13
•
Granted: 1988-09-06
•
Expires: 2007-11-13
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Compounds of the formula: ##STR1## wherein R 1 is (1) hydrogen, (2) C 1 to C 4 alkyl, (3) C 2 to C 4 alkenyl, or (4) NR 2 R 3 , wherein R 2 and R 3 are independently selected from hydrogen, C 1 to C 4 alkyl and hydroxyl, but R 2 and R 3 are not simultaneously hydroxyl; X is (1) oxygen, (2) sulfur, (3) SO 2 , or (4) NR 4 , wherein R 4 is (1) hydrogen, (2) C 1 to C 6 alkyl, (3) C 1 to C 6 alkoyl or (4) aroyl; A is selected from C 1 to C 6 alkylene and C 2 to C 6 alkenylene; n is 0-4; Y is selected independently at each occurrence from (1) hydrogen, (2) halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C 1 to C 12 alkyl, (7) C 2 to C 12 alkenyl, (8) C 1 to C 12 alkoxy, (9) C 3 to C 8 cycloalkyl, (10) aryl, (11) aryloxy, (12) aroyl, (13) C 1 to C 12 arylalkyl, (14) C 2 to C 12 arylalkenyl, (15) C 1 to C 12 arylalkoxy, (16) C 1 to C 12 arylthioalkoxy, and substituted derivatives fo (17) aryl, (18) aryloxy, (19) aroyl, (20) C 1 to C 12 arylalkyl, (21) C 2 to C 12 arylalkenyl, (22) C 1 to C 12 arylalkoxy, or (23) C 1 to C 12 arylthioalkoxy, wherein substituents are selected from halo, nitro, cyano, C 1 to C 12 alkyl, alkoxy, and halosubstituted alkyl; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C 1 to C 12 , alkoyl are potent inhibitors of 5- and/or 12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting compositions and a method of inhibiting lipoxygenase.

Inventors

  • 👤 James B. Summers
  • 👤 Jimmie L. Moore

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 00:40
CPC Classifications
C; C07; C07D; C07D307/00; C07D307/77; C07D307/91; C07D209/00; C07D209/56; C07D209/80; C07D209/82; C07D209/86; C07D333/00; C07D333/50; C07D333/76

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 85 words
A compound of the formula: ##STR10## wherein R 1 is (1) hydrogen, (2) C 1 to C 4 alkyl, (3) C 2 to C 4 alkenyl, or (4) NR 2 R 3 , wherein R 2 and R 3 are independently selected from hydrogen, C 1 to C 4 alkyl and hydroxyl, but R 2 and R 3 are not simultaneously hydroxyl; X is oxygen, A is selected from C 1 to C 6 alkylene and C 2 to C 6 alkenylene; n is 0-4;
Claim 2
Dependent Claim 85 words
A compound of the formula: ##STR10## wherein R 1 is (1) hydrogen, (2) C 1 to C 4 alkyl, (3) C 2 to C 4 alkenyl, or (4) NR 2 R 3 , wherein R 2 and R 3 are independently selected from hydrogen, C 1 to C 4 alkyl and hydroxyl, but R 2 and R 3 are not simultaneously hydroxyl; X is oxygen, A is selected from C 1 to C 6 alkylene and C 2 to C 6 alkenylene; n is 0-4;
Claim 3
Dependent Claim 130 words
Y is selected independently at each occurrence from halogen, hydroxy, cyano, halosubstituted alkyl, C 1 to C 12 alkyl, C 2 to C 12 alkenyl, C 1 to C 12 alkoxy, C 3 to C 8 cycloalkyl, aryl, aryloxy, aroyl, C 1 to C 12 arylalkyl, C 2 to C 12 arylalkenyl, C 1 to C 12 arylalkoxy, C 1 to C 12 arylthioalkoxy, and substituted derivatives of aryl, aryloxy, aroyl, C 1 to C 12 arylalkyl, C 2 to C 12 arylalkenyl, C 1 to C 12 arylalkoxy, or C 1 to C 12 arylthioalkoxy, wherein substituents are selected from halo, nitro, cyano, C 1 to C 12 alkyl, alkoxy, and halosubstituted alkyl; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C 1 to C 12 alkoyl.
Claim 4
Dependent Claim 130 words
Y is selected independently at each occurrence from halogen, hydroxy, cyano, halosubstituted alkyl, C 1 to C 12 alkyl, C 2 to C 12 alkenyl, C 1 to C 12 alkoxy, C 3 to C 8 cycloalkyl, aryl, aryloxy, aroyl, C 1 to C 12 arylalkyl, C 2 to C 12 arylalkenyl, C 1 to C 12 arylalkoxy, C 1 to C 12 arylthioalkoxy, and substituted derivatives of aryl, aryloxy, aroyl, C 1 to C 12 arylalkyl, C 2 to C 12 arylalkenyl, C 1 to C 12 arylalkoxy, or C 1 to C 12 arylthioalkoxy, wherein substituents are selected from halo, nitro, cyano, C 1 to C 12 alkyl, alkoxy, and halosubstituted alkyl; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C 1 to C 12 alkoyl.
Claim 5
Dependent Claim 13 words
A compound according to claim 1 wherein R 1 is CH 3 .
Claim 6
Dependent Claim 13 words
A compound according to claim 1 wherein R 1 is NH 2 .
Claim 7
Dependent Claim 12 words
A compound according to claim 1 wherein A is --CHCH 3 --.
Claim 8
Dependent Claim 30 words
A method for inhibiting 5-and/or 12-lipoxygenase activity comprising administering to a human or lower animal in need of such treatment, a therapeutically effective amount of a compound of claim 1.
Claim 9
Dependent Claim 12 words
The method of claim 5 wherein R 1 is CH 3 .
Claim 10
Dependent Claim 12 words
The method of claim 5 wherein R 1 is NH 2 .
Claim 11
Dependent Claim 11 words
The method of claim 5 wherein A is --CHCH 3 --.
Claim 12
Dependent Claim 23 words
A pharmaceutical composition for inhibiting 5- and/or 12-lipoxygenase, comprising a pharmaceutical carrier and a therapeutically effective amount of a compound of claim 1.

References Cited (Backward Citations)

US3657281A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1991-09-06 1992-03-07 1992-09-06 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1995-09-06 1996-03-07 1996-09-06 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1999-09-06 2000-03-07 2000-09-06 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag